Universidade Federal da Bahia (UFBA), Programa de Pós Graduação em Processos Interativos dos Órgãos e Sistemas (PPGPIOS), Salvador, BA, Brazil.
Universidade Federal da Bahia (UFBA), Faculdade de Medicina, Departamento de Pediatria - Setor de Cardiopediatria, Salvador, BA, Brazil.
J Pediatr (Rio J). 2019 Jul-Aug;95(4):475-481. doi: 10.1016/j.jped.2018.05.006. Epub 2018 Jun 27.
Mucopolysaccharidosis is a rare genetic disease characterized by the intralysosomal deposition of glycosaminoglycans. Cardiovascular impairment is a common feature. Cardiac signs and symptoms are underestimated due to the disease involvement in other organs. Enzyme replacement therapy can be used in mucopolysaccharidosis I, II, IV, and VI. Thus, the knowledge about the use of new echocardiography tools is relevant to improve the care of this population. This study aimed to describe left ventricular function assessment by conventional echocardiography and left ventricular global longitudinal strain analysis and compare the alterations in patients receiving enzyme replacement therapy and who had different ages at the start of therapy.
Outpatient-based descriptive study. The patients were submitted to conventional echocardiography and left ventricular global longitudinal strain measurement.
Sixteen patients were evaluated; median age of 14.2 years (SD=5.2 years). Left ventricular hypertrophy was found in nine patients (56.2%). All patients had preserved left ventricular systolic function (Simpson and Teichholz). Nine (56.2%) patients showed alterations in left ventricular global longitudinal strain. The study showed a positive association between left ventricular hypertrophy and alteration in the left ventricular global longitudinal strain, and late start of enzyme replacement therapy and alteration in the left ventricular global longitudinal strain.
Echocardiographic alterations in patients with mucopolysaccharidosis were frequently observed, especially alterations in the left ventricular geometry and subclinical dysfunction. Patients who had a late enzyme replacement therapy start showed an association with worse left ventricular global longitudinal strain values, reinforcing the need for early diagnosis and treatment. The use of new echocardiographic tools may improve the follow-up of these patients.
黏多糖贮积症是一种罕见的遗传性疾病,其特征为溶酶体内糖胺聚糖沉积。心血管损伤是其常见特征。由于该疾病还会累及其他器官,因此心脏的体征和症状常被低估。黏多糖贮积症 I、II、IV 和 VI 型均可采用酶替代疗法。因此,了解新的超声心动图工具的应用对于改善此类人群的治疗非常重要。本研究旨在描述常规超声心动图和左心室整体纵向应变分析评估左心室功能,并比较接受酶替代疗法和不同起始治疗年龄的患者的变化。
这是一项基于门诊的描述性研究。患者接受常规超声心动图和左心室整体纵向应变测量。
共评估了 16 例患者,平均年龄为 14.2 岁(标准差=5.2 岁)。9 例(56.2%)患者存在左心室肥厚。所有患者的左心室收缩功能均正常(辛普森和泰奇霍兹法)。9 例(56.2%)患者的左心室整体纵向应变发生改变。研究表明,左心室肥厚与左心室整体纵向应变改变之间存在正相关,以及酶替代疗法起始时间晚与左心室整体纵向应变改变之间存在正相关。
黏多糖贮积症患者的超声心动图改变较为常见,尤其是左心室几何结构和亚临床功能障碍。酶替代疗法起始时间晚的患者与更差的左心室整体纵向应变值相关,这进一步强调了早期诊断和治疗的必要性。新的超声心动图工具的应用可能会改善这些患者的随访。